Cronos Group Inc.CRON stock score: 59/100
$3.08 · -2.84% · Scored Nov 19, 2026
- Technical
- 46
- Fundamental
- 62
- News
- —
The reading
Cronos Group (CRON) scores 59 out of 100, which reads neutral, higher than 72% of Healthcare stocks and 74% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 62, technicals 46.
Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Earnings Growth (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 30 and contrarian oscillators 72 — a split worth reading before trusting the technical total.
Since Aug 24, 2026 the composite has ranged from 55 to 62, and it ends the period where it started.
About Cronos Group
Cronos Group (CRON) is a cannabinoid company that produces and sells cannabis products in Canada, Israel and Germany, along with other international markets. In Canada, its Spinach brand is one of the larger names, selling edibles, vapes, pre-rolls and dried flower through provincial distributors and licensed retail stores. Under its PEACE NATURALS brand, it sells medical cannabis in Israel and exports flower to Germany and other countries where medical cannabis is legal. Cronos grows cannabis at its own facilities and through Cronos GrowCo, a large greenhouse operation in Ontario in which it holds an interest. The company earns money from wholesale sales of its products to distributors, retailers and pharmacies, and it also earns interest on a large cash balance. Altria is one of its largest shareholders.
Cronos competes with other licensed cannabis producers such as Tilray Brands, Canopy Growth, Organigram and SNDL, as well as with illicit sellers and local producers in its international markets. Its edge rests on well-known consumer brands in Canada, a growing medical business abroad and a strong balance sheet with substantial cash and no significant debt. Investors who follow CRON stock tend to watch net revenue growth and Spinach’s market share in Canada. Growth in Israel and Germany is closely followed. Gross margins, excise taxes and pricing, cannabis regulation in its markets, use of its cash and share buybacks are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward CRON’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
62Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Holding it back
Net income growth from the prior fiscal year to the latest.
5-year earnings growth evaluates long-term profit trajectory and consistency.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
37Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Williams %R (14-period) measures where the current price sits within the recent high-low range.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 32 | 1 |
| Daily | 37 | 3 |
| Weekly | 57 | 2 |
| Monthly | 55 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 59 |
| Nov 19, 2026 | 59 |
| Nov 18, 2026 | 59 |
| Nov 16, 2026 | 61 |
| Nov 15, 2026 | 61 |
| Nov 14, 2026 | 61 |
| Nov 13, 2026 | 62 |
| Nov 12, 2026 | 56 |
| Nov 11, 2026 | 56 |
| Nov 8, 2026 | 59 |
| Nov 7, 2026 | 59 |
| Nov 6, 2026 | 60 |
| Nov 5, 2026 | 60 |
| Nov 4, 2026 | 60 |
| Nov 3, 2026 | 60 |
| Nov 2, 2026 | 56 |
| Oct 31, 2026 | 57 |
| Oct 30, 2026 | 59 |
| Oct 29, 2026 | 58 |
| Oct 28, 2026 | 59 |
| Oct 27, 2026 | 58 |
| Oct 26, 2026 | 58 |
| Oct 25, 2026 | 58 |
| Oct 24, 2026 | 58 |
| Oct 23, 2026 | 60 |
| Oct 22, 2026 | 59 |
| Oct 21, 2026 | 58 |
| Oct 20, 2026 | 57 |
| Oct 19, 2026 | 57 |
| Oct 18, 2026 | 57 |
| Oct 17, 2026 | 57 |
| Oct 16, 2026 | 56 |
| Oct 15, 2026 | 55 |
| Oct 14, 2026 | 56 |
| Oct 13, 2026 | 56 |
| Oct 12, 2026 | 56 |
| Oct 11, 2026 | 56 |
| Oct 10, 2026 | 56 |
| Oct 9, 2026 | 55 |
| Oct 8, 2026 | 56 |
| Oct 7, 2026 | 57 |
| Oct 6, 2026 | 57 |
| Oct 5, 2026 | 57 |
| Oct 3, 2026 | 57 |
| Oct 2, 2026 | 56 |
| Oct 1, 2026 | 57 |
| Sep 30, 2026 | 58 |
| Sep 29, 2026 | 58 |
| Sep 27, 2026 | 57 |
| Sep 26, 2026 | 57 |
| Sep 25, 2026 | 58 |
| Sep 24, 2026 | 59 |
| Sep 23, 2026 | 60 |
| Sep 22, 2026 | 59 |
| Sep 21, 2026 | 59 |
| Sep 19, 2026 | 59 |
| Sep 18, 2026 | 59 |
| Sep 17, 2026 | 58 |
| Sep 16, 2026 | 57 |
| Sep 15, 2026 | 57 |
| Sep 13, 2026 | 57 |
| Sep 12, 2026 | 56 |
| Sep 11, 2026 | 56 |
| Sep 10, 2026 | 56 |
| Sep 9, 2026 | 58 |
| Sep 8, 2026 | 58 |
| Sep 7, 2026 | 58 |
| Sep 6, 2026 | 58 |
| Sep 5, 2026 | 58 |
| Sep 4, 2026 | 58 |
| Sep 3, 2026 | 58 |
| Sep 2, 2026 | 59 |
| Sep 1, 2026 | 58 |
| Aug 31, 2026 | 58 |
| Aug 30, 2026 | 58 |
| Aug 29, 2026 | 58 |
| Aug 28, 2026 | 59 |
| Aug 27, 2026 | 60 |
| Aug 26, 2026 | 60 |
| Aug 25, 2026 | 60 |
| Aug 24, 2026 | 59 |
Key facts
- Market cap
- $1.1B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 1.25
- Risk grade (1–10)
- 6
- Next earnings
- Nov 5, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| ANIP ANI Pharmaceuticals | $1.6B | 67 |
| ALVO Alvotech | $1.5B | 55 |
| PCRX Pacira BioSciences | $1.5B | 65 |
| PAHC Phibro Animal Health | $1.4B | 63 |
| HROW Harrow | $1.2B | 57 |
| AMPH Amphastar Pharmaceuticals | $1.2B | 62 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is CRON's stock rating today?
CRON scores 59/100 (Neutral) as of Nov 19, 2026: technical 46, fundamental 62. Scores are recomputed every night.
What does Cronos Group do?
Cronos Group (CRON) is a cannabinoid company that produces and sells cannabis products in Canada, Israel and Germany, along with other international markets. In Canada, its Spinach brand is one of the larger names, selling edibles, vapes, pre-rolls and dried flower through provincial distributors and licensed retail stores.
Is CRON stock a buy?
The score is not a buy or sell recommendation. A 59 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the CRON score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/cron/"><img src="https://stocksscores.com/stocks/cron/badge.svg" alt="CRON stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/cron/)